Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk has struggled to meet the demand ... The company sold its pen needles and blood glucose monitoring systems (BGM) business to Medical Technology and Devices (MTD) for an undisclosed ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

(Bloomberg) -- Novo Nordisk A/S is following in rival ... Novo’s direct-to-consumer medicine will come in a pen device with a hidden needle. However, as Novo will only provide Wegovy to patients ...